Literature DB >> 11115562

Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.

J I Izawa1, J W Slaton, D Kedar, T Karashima, P Perrotte, B Czerniak, H B Grossman, C P Dinney.   

Abstract

It is generally accepted that there are dichotomous biologic pathways that lead to the development of either: i) superficial papillary (Ta) transitional cell carcinoma (TCC) or ii) precursor lesions to muscle-invasive (CIS, T1) TCC and muscle-invasive (> or =T2) TCC. We investigated the expression of several progression-related genes to characterize the phenotype of these tumors within these divergent developmental pathways. Using a colorimetric in situ hybridization technique, we examined the expression of mRNAs of several progression-related genes in archival, pathologic specimens from 77 patients with bladder TCC. These genes included basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), interleukin (IL)-8, matrix metalloproteinase (MMP)-9, and epidermal growth factor receptor (EGFR). Relative gene expression was quantified using image analysis. Gene expression was normalized using poly (dT) and the expression of each factor in a panel of specimens of normal urothelium. Patients were stratified according to disease stage, and the level of gene expression among the stratified groups was compared. VEGF, bFGF, IL-8, and MMP-9 expression was increased in muscle-invasive compared with superficial papillary tumors, (p<0.05) and VEGF expression was increased in muscle-invasive tumors compared with CIS specimens (p<0. 05). bFGF, IL-8, and EGFR expression was increased in CIS specimens compared with superficial papillary tumors (p<0.05). The pattern of expression of bFGF, VEGF, IL-8, MMP-9, and EGFR represent the divergent developmental pathways in the pathogenesis of bladder TCC, which characterizes superficial or invasive bladder cancer. bFGF, IL-8, and EGFR appear to be upregulated in early precursor lesions (CIS), whereas VEGF appears to be upregulated at later stages in the development of muscle-invasive TCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11115562     DOI: 10.3892/or.8.1.9

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

1.  Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

Authors:  Haris Zahoor; Maria C Mir; Pedro C Barata; Andrew J Stephenson; Steven C Campbell; Amr Fergany; Robert Dreicer; Jorge A Garcia
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

Review 2.  Targeting angiogenesis in bladder cancer.

Authors:  Aymen A Elfiky; Jonathan E Rosenberg
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

3.  Interleukin-8 (IL-8) over-production and autocrine cell activation are key factors in monomethylarsonous acid [MMA(III)]-induced malignant transformation of urothelial cells.

Authors:  C Escudero-Lourdes; T Wu; J M Camarillo; A J Gandolfi
Journal:  Toxicol Appl Pharmacol       Date:  2011-10-10       Impact factor: 4.219

Review 4.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Lauren Marquis; Frances Martin; Michael B Williams; Jay Shah; Robert Svatek; Aditi Das; Liana Adam; Ashish Kamat; Arlene Siefker-Radtke; Colin Dinney
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

Review 5.  State-of-the-art management of metastatic disease at initial presentation or recurrence.

Authors:  Fabio Calabrò; Cora N Sternberg
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

6.  Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke.

Authors:  Arshad Rahmani; Mohammad Alzohairy; Habeeb Khadri; Ashish K Mandal; Moshahid A Rizvi
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

Review 7.  [Targeted therapy of urological tumours. Experimental field or established therapeutic approach?].

Authors:  M W Kramer; S Krege; I Peters; A S Merseburger; M A Kuczyk
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

8.  Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma.

Authors:  Francisco Ayala de la Peña; Keizo Kanasaki; Megumi Kanasaki; Neelima Tangirala; Genta Maeda; Raghu Kalluri
Journal:  J Biol Chem       Date:  2011-03-09       Impact factor: 5.157

9.  Expression of pigment epithelium-derived factor in bladder tumour is correlated with interleukin-8 yet not with interleukin-1α.

Authors:  Chenchen Feng; Ming Guan; Qiang Ding; Yuanfang Zhang; Haowen Jiang; Hui Wen; Paohsun Wang; Zhong Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-02-19

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.